ArticleScientific reports2022
Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 65 citations in OpenAlex.
- Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapy.Cell reports. Medicine · 2025Trial
- An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.Oncoimmunology · 2026Article
- An immunocompetent transplantable mouse model of basal cell carcinoma.JID innovations : skin science from molecules to population health · 2026Article
- Review
- Epigenetic plus cytokine therapy induces stem-like CD8Journal for immunotherapy of cancer · 2026Article
- Cellular Consequences, Citrullination Substrates, and Antigenicity of Targeting PAD4 to Cell Surfaces.ACS central science · 2026Article
- Vaccination with cationic liposome-encapsulated CD4 and CD8 T cell neoepitopes induces superior tumor control.Materials today. Bio · 2026Article
- A fully human pan VL9 HLA-E TCRm antibody enables functional dissection of HLA-E biology and checkpoint signaling.iScience · 2026Article
- A novel colchicine-binding site inhibitor suppresses triple-negative breast cancer growth and metastasis and synergizes with anti-PD-L1 immunotherapy in an immunogenic cancer model.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026Article
- Microbial-derived immunostimulatory small molecule augments anti-PD-1 therapy in lung cancer.Cell reports. Medicine · 2026Article
- Cellular consequences, citrullination substrates, and antigenicity resulting from wild-type and targeted PAD4 on cell surfaces.bioRxiv : the preprint server for biology · 2026Article
- Monitoring systemic immune responses to checkpoint inhibition in breast cancer reveals host responses and mechanisms of resistance.Journal for immunotherapy of cancer · 2025Article
- Precision Targeting of Myeloid Cells via Peptide Dendrimer-Lipid Nanocarriers: A Novel Platform for Potent Cancer Immunotherapies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Timing of immune checkpoint blockade shapes anti-tumor immunity via a clock-dependent chemokine axis.bioRxiv : the preprint server for biology · 2025Article
- Impact of physical and psychological stressors on tumor growth and immune responses in breast cancer.Comprehensive psychoneuroendocrinology · 2025Article
- VEGFR2 blockade converts thermally ablative focused ultrasound into a potent driver of T cell-dependent anti-tumor immunity.bioRxiv : the preprint server for biology · 2025Article
- Targeted Hyaluronan Degradation Enhanced Tumor Growth Inhibition in Gastrointestinal Cancer Models.Cancers · 2025Article
- Base-editing a single missense mutation in A20 enhances CAR-T cell efficacy.bioRxiv : the preprint server for biology · 2025Article
- Article
- RTP4 Suppresses Colorectal Cancer Progression via MHC-I-Mediated CD8Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancers are immunologically heterogeneous. A range of immunotherapies target abnormal tumor immunity via different mechanisms of actions (MOAs), particularly various tumor-infiltrate leukocytes (TILs). We modeled loss of function (LOF) in four common anti-PD-1 antibody-responsive syngeneic tumors, MC38, Hepa1-6, CT-26 and EMT-6, by systematical depleting a series of TIL lineages to explore the mechanisms of tumor immunity and treatment. CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.